Zelluna（7UM0）株式概要ゼルナASAは固形がん治療用のT細胞受容体（TCR）細胞免疫療法製品を開発している。 詳細7UM0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( NOK8K )過去5年間で収益は年間23.8%減少しました。 意味のある時価総額がありません ( €59M )すべてのリスクチェックを見る7UM0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€1.966.5m% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-133m13m2016201920222025202620282031Revenue NOK 8.0kEarnings NOK 1.4kAdvancedSet Fair ValueView all narrativesZelluna ASA 競合他社2investSymbol: XTRA:2INVMarket cap: €62.9mGenetic AnalysisSymbol: DB:8V8Market cap: €46.2m2investSymbol: DB:2INVMarket cap: €45.1mNovogeniaSymbol: MUN:7V0Market cap: €78.0m価格と性能株価の高値、安値、推移の概要Zelluna過去の株価現在の株価NOK 1.9652週高値NOK 2.9852週安値NOK 0.68ベータ01ヶ月の変化20.31%3ヶ月変化-3.22%1年変化73.93%3年間の変化n/a5年間の変化n/aIPOからの変化17.07%最新ニュースお知らせ • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.お知らせ • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.お知らせ • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).お知らせ • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.お知らせ • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.お知らせ • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).お知らせ • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 27Zelluna ASA, Annual General Meeting, Apr 23, 2026Zelluna ASA, Annual General Meeting, Apr 23, 2026, at 09:00 W. Europe Standard Time.お知らせ • Feb 21Zelluna Receives Uk Mhra and Ethics Approval to Initiate Zima-101 First-In-Human Clinical TrialZelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating Zelluna-MA4-1, Zelluna's lead TCR-NK product candidate. MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK, marking a key milestone in the Company's transition from preclinical to clinical-stage development and representing the first clinical evaluation of its proprietary TCR-NK platform. ZIMA-101 is designed to assess the safety, tolerability, and preliminary clinical activity of ZI-MA4-1 in patients with advanced solid cancers, including lung cancer, ovarian, head and neck cancer, and sarcomas. ZIMA-1 is an off-the-shelf cell therapy that combines two powerful cancer fighting mechanisms: the precise solid tumour targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. This approach is designed to address key limitations that have prevented existing cell therapies from working effectively in solid tumours. ZIMA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovarian, head and neck and sarcomas. ZI-MA4- 1 has broad intellectual property coverage, including a landmark granted patent providing dominant protection for Zelluna over the entire TCR-NK field. The UK MHRA offers a well-established regulatory framework for advanced therapies, including early-phase clinical development of Advanced Therapy Medicinal Products (ATMPs), providing an efficient and supportive environment for pioneering modalities such as TCR-NK therapies. The trial will be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust (Manchester, UK) with participation from Dr. Andrew Furness at The Royal Marsden (London, UK), both world leading centres for oncology and early-phase cell therapy clinical research.お知らせ • Feb 05Zelluna ASA Promotes Emilie Gauthy to Chief Technology OfficerZelluna ASA announced the promotion of Emilie Gauthy to Chief Technology Officer (CTO). Gauthy, who has played a central role in building Zelluna's manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.in her role as CTO, Gauthy will continue to lead Zelluna's manufacturing and CMC strategy as the company advances its clinical development program, scales up manufacturing capacity and expands the pipeline of its off-the-shelf TCR-NK platform. Under Gauthy's leadership, Zelluna has established a scalable manufacturing process and analytical capabilities that enabled the company to successfully submit its Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in December 2025. Key achievements include locking the manufacturing process, producing and quality-testing a GMP clinical batch, and establishing the CMC foundation for the company's first-in-human clinical trial, with initial data expected to emerge from mid-2026. These achievements also enable the entire TCR-NK platform supporting the continuous development of future programs.お知らせ • Dec 13Zelluna Completes First Gmp Batch of Zi-Ma4-1, A Novel Tcr-Nk Cell Therapy, to Treat Patients in Upcoming First-In-Human TrialZelluna announced the successful manufacture and QC (Quality Control) testing of the first GMP (Good Manufacturing Practice) batch of its lead candidate, ZI-MA4-1. This material is intended for use in Zelluna's upcoming first-in-human clinical trial, marking a major milestone in the company's progress toward regulatory submission and patient dosing. The GMP batch was successfully produced using Zelluna's proprietary manufacturing process, which was finalised and locked in April 2025. The process is designed to deliver high-quality TCR-NK products, with the ability to generate hundreds of doses from a single manufacturing run, offering both broad patient access and cost-of-goods advantages. Zelluna remains on track to submit a CTA for ZI-MA4- 1 in 2H 2025 with initial clinical data expected mid-2026.お知らせ • Dec 09+ 5 more updatesZelluna ASA to Report Fiscal Year 2026 Results on Mar 31, 2027Zelluna ASA announced that they will report fiscal year 2026 results on Mar 31, 2027お知らせ • Nov 28Zelluna Asa Announces CFO ChangesZelluna announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter. Geir Christian brings extensive senior leadership experience across the Norwegian biotech and life sciences sector, including multiple CFO and CEO roles in both publicly listed and privately held companies including in Algeta and Photocure. Over his career, he has led financial operations, corporate strategy, and capital market engagement for several life science organisations, giving him a deep understanding of the financial, regulatory, and operational demands of the industry.Geir Christian has also been part of Zelluna as Finance Director for over seven years, holding a key leadership role across finance and operations. He brings strong familiarity with Zelluna’s TCR-NK platform, financial strategy, and organisational priorities.お知らせ • Nov 04+ 2 more updatesZelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million.Zelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million. Security Name: Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 10 Transaction Features: Rights Offeringお知らせ • Oct 10Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-In-Human Trials in the UKZelluna announced it has received positive feedback from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) following recent scientific advice. This feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for ZI-MA4-1 and supports Zelluna's planned Clinical Trial Application (CTA) submission later this year. In parallel, Zelluna has advanced preparations for the first-in-human trial of ZI-MA4- 1 by engaging with leading UK cancer centres and appointing Professoriona Thistlethwaite, Medical Oncology Consultant at The Christie in Manchester, as proposed Chief Investigator. The Christie, one of Europe's leading cancer centres and a major hub for advanced cell therapy research, will serve as a lead site for the study. Both Professor Fiona Thistlethwaite at The Christie and Dr. Andrew Furness at The Royal Marsden in London, a global leader in oncology and early-phase cell therapy studies, are expected to play central roles in the trial and have contributed to shaping its design and development strategy. Subject to CTA approval, the proposed Phase I trial will be an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4 -1 across multiple solid tumours. Prof. Fiona Thistlethwaite, medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie, and proposed Chief Investigator for the planned trial, said "I am genuinely excited to see the progress of ZI-MA 4-1 into the clinic. I am optimistic that the dual killing mechanism of the NK cells and tumour antigen directed TCR will provide with the step-change that need in the solid tumour setting to provide the required level of tumour potential whilst avoiding tumour escape".お知らせ • Apr 08+ 4 more updatesZelluna ASA to Report Q1, 2025 Results on May 08, 2025Zelluna ASA announced that they will report Q1, 2025 results on May 08, 2025株主還元7UM0DE BiotechsDE 市場7D-0.3%-0.1%0.1%1Y73.9%11.4%-0.5%株主還元を見る業界別リターン: 7UM0過去 1 年間で11.4 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: 7UM0過去 1 年間で-0.5 % の収益を上げたGerman市場を上回りました。価格変動Is 7UM0's price volatile compared to industry and market?7UM0 volatility7UM0 Average Weekly Movement7.3%Biotechs Industry Average Movement7.7%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: 7UM0 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 7UM0の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201615Namir Hassanzelluna.comZelluna ASAは固形がん治療用のT細胞受容体（TCR）細胞免疫療法製品を開発している。同社は2016年に設立され、ノルウェーのオスロを拠点としている。もっと見るZelluna ASA 基礎のまとめZelluna の収益と売上を時価総額と比較するとどうか。7UM0 基礎統計学時価総額€58.87m収益（TTM）-€12.13m売上高(TTM)€731.06Over9,999xP/Sレシオ-4.9xPER（株価収益率7UM0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7UM0 損益計算書（TTM）収益NOK 8.00k売上原価NOK 0売上総利益NOK 8.00kその他の費用NOK 132.74m収益-NOK 132.73m直近の収益報告Mar 31, 2026次回決算日Aug 20, 2026一株当たり利益（EPS）-4.51グロス・マージン100.00%純利益率-1,659,125.00%有利子負債／自己資本比率0%7UM0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 00:29終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Zelluna ASA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Geir HolomDNB Carnegie
お知らせ • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.
お知らせ • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.
お知らせ • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.
New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).
お知らせ • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 14Zelluna ASA Doses First Solid Tumour Patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trialZelluna ASA announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate. The first patient was treated at The Christie NHS Foundation Trust in the United Kingdom, the largest single site cancer centre in Europe and the lead clinical site for the study. ZIMA-101 is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development, in patients with advanced MAGE-A4-positive solid tumours. MAGE-A4 is present in several common cancer types, including ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer. ZIMA-101 also represents the first clinical evaluation of Zelluna's proprietary TCR-NK platform and builds on years of scientific innovation, preclinical research and manufacturing development. The study is now active at two clinical sites in the United Kingdom: The Christie and The Royal Marsden NHS Foundation Trusts. Patient identification, pre-screening and screening activities continue across all four tumour indications included in the ZIMA-101 study. Zelluna expects initial clinical data from the ZIMA-101 study to emerge from mid-2026. ZIMA-101 is a first-in-human, multicentre Phase 1 dose-escalation study evaluating the safety, tolerability and preliminary anti-tumour activity of ZI-MA4-1 in patients with advanced MAGE-A4-positive solid tumours. The study is being conducted at The Christie and The Royal Marsden NHS Foundation Trusts in the United Kingdom. The study follows a dose escalation design (3+3) with three predefined dose levels and three patients per dose level. Each patient will receive three doses on Days 1, 4 and 8 of a treatment cycle. For the first patient at each dose level, an Independent Data Monitoring Committee will review the patient's data following completion of the initial safety observation period before providing recommendations on enrolment of the remaining two patients at that dose level. ZI-MA4-1 is Zelluna's lead allogeneic (off the shelf) TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK cell therapy in clinical development. The product combines the innate tumour-killing properties of NK cells with precision tumour targeting enabled by affinity engineered T cell receptors (TCRs), with the goal of addressing key limitations of existing cell therapies in solid tumours, including scalability, tumour targeting and access.
お知らせ • Jun 29Zelluna Activates Second Clinical Site For ZIMA-101 Phase 1 Clinical Trial Evaluating ZI-MA4-1Zelluna announced that The Royal Marsden NHS Foundation Trust has been activated as the second clinical site in the ZIMA-101 Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate. The activation of this second clinical site further expands the Company's clinical execution capabilities and patient recruitment capacity as ZIMA-101 progresses through its early stages. The site will soon be in a position to actively identify and screen patients with suitable tumour types, characteristics (including expression of the MAGE-A4 antigen and HLA-A*02 positivity) and disease stage for potential enrolment. The activation of The Royal Marsden follows the activation of the first clinical site, The Christie NHS Foundation Trust. With both sites now activated, the ZIMA-101 programme has full clinical execution capability across two of the UK's leading cancer centres. ZIMA-101 is a first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna's lead TCR-NK product candidate and the world's first MAGE-A4-targeting TCR-NK therapy in clinical development. The study marks the first clinical evaluation of Zelluna's proprietary TCR-NK platform. Zelluna remains on track for initial clinical data from the ZIMA-101 study to emerge from mid-2026.
お知らせ • Jun 27Zelluna Reports Final Readout From Legacy Ultimovacs DOVACC Phase II Trial For UV1 Cancer VaccineZelluna announced that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. The investigator-led Phase II DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet its primary endpoint of progression free survival (PFS). The DOVACC readout represents the final Phase II outcome for the UV1 programme; all five Phase II studies evaluating UV1 did not meet their primary endpoints. Aside from minimal costs associated with completing the remaining study close-out activities, Zelluna does not expect to incur any further material costs related to the UV1 programme which is now considered concluded. The DOVACC trial tested the cancer vaccine UV1 in patients with BRCAwt platinum sensitive recurrent ovarian cancer. The goal was to assess whether UV1, given alongside two established cancer medicines, could slow disease progression better than standard treatment alone. The DOVACC readout represents the fifth Phase II study evaluating UV1 that has not met its primary endpoint.
New Risk • Jun 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Revenue is less than US$1m (kr8.0k revenue, or US$826). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€50.3m market cap, or US$57.7m).
お知らせ • Jun 18+ 2 more updatesZelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million.Zelluna ASA has completed a Follow-on Equity Offering in the amount of NOK 3.163223 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 170,985 Price\Range: NOK 18.5
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Co-Founder & Chairman Anders Tuv was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 27Zelluna ASA, Annual General Meeting, Apr 23, 2026Zelluna ASA, Annual General Meeting, Apr 23, 2026, at 09:00 W. Europe Standard Time.
お知らせ • Feb 21Zelluna Receives Uk Mhra and Ethics Approval to Initiate Zima-101 First-In-Human Clinical TrialZelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Company's Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase 1 clinical trial evaluating Zelluna-MA4-1, Zelluna's lead TCR-NK product candidate. MHRA and Ethics approvals enable Zelluna to initiate first-in-human clinical trial in the UK, marking a key milestone in the Company's transition from preclinical to clinical-stage development and representing the first clinical evaluation of its proprietary TCR-NK platform. ZIMA-101 is designed to assess the safety, tolerability, and preliminary clinical activity of ZI-MA4-1 in patients with advanced solid cancers, including lung cancer, ovarian, head and neck cancer, and sarcomas. ZIMA-1 is an off-the-shelf cell therapy that combines two powerful cancer fighting mechanisms: the precise solid tumour targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. This approach is designed to address key limitations that have prevented existing cell therapies from working effectively in solid tumours. ZIMA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovarian, head and neck and sarcomas. ZI-MA4- 1 has broad intellectual property coverage, including a landmark granted patent providing dominant protection for Zelluna over the entire TCR-NK field. The UK MHRA offers a well-established regulatory framework for advanced therapies, including early-phase clinical development of Advanced Therapy Medicinal Products (ATMPs), providing an efficient and supportive environment for pioneering modalities such as TCR-NK therapies. The trial will be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust (Manchester, UK) with participation from Dr. Andrew Furness at The Royal Marsden (London, UK), both world leading centres for oncology and early-phase cell therapy clinical research.
お知らせ • Feb 05Zelluna ASA Promotes Emilie Gauthy to Chief Technology OfficerZelluna ASA announced the promotion of Emilie Gauthy to Chief Technology Officer (CTO). Gauthy, who has played a central role in building Zelluna's manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect.in her role as CTO, Gauthy will continue to lead Zelluna's manufacturing and CMC strategy as the company advances its clinical development program, scales up manufacturing capacity and expands the pipeline of its off-the-shelf TCR-NK platform. Under Gauthy's leadership, Zelluna has established a scalable manufacturing process and analytical capabilities that enabled the company to successfully submit its Clinical Trial Application (CTA) for ZI-MA4-1 to the UK MHRA in December 2025. Key achievements include locking the manufacturing process, producing and quality-testing a GMP clinical batch, and establishing the CMC foundation for the company's first-in-human clinical trial, with initial data expected to emerge from mid-2026. These achievements also enable the entire TCR-NK platform supporting the continuous development of future programs.
お知らせ • Dec 13Zelluna Completes First Gmp Batch of Zi-Ma4-1, A Novel Tcr-Nk Cell Therapy, to Treat Patients in Upcoming First-In-Human TrialZelluna announced the successful manufacture and QC (Quality Control) testing of the first GMP (Good Manufacturing Practice) batch of its lead candidate, ZI-MA4-1. This material is intended for use in Zelluna's upcoming first-in-human clinical trial, marking a major milestone in the company's progress toward regulatory submission and patient dosing. The GMP batch was successfully produced using Zelluna's proprietary manufacturing process, which was finalised and locked in April 2025. The process is designed to deliver high-quality TCR-NK products, with the ability to generate hundreds of doses from a single manufacturing run, offering both broad patient access and cost-of-goods advantages. Zelluna remains on track to submit a CTA for ZI-MA4- 1 in 2H 2025 with initial clinical data expected mid-2026.
お知らせ • Dec 09+ 5 more updatesZelluna ASA to Report Fiscal Year 2026 Results on Mar 31, 2027Zelluna ASA announced that they will report fiscal year 2026 results on Mar 31, 2027
お知らせ • Nov 28Zelluna Asa Announces CFO ChangesZelluna announced the appointment of Geir Christian Melen as new Chief Financial Officer, effective 01 January 2026. Hans Vassgård Eid will be stepping down as CFO of Zelluna ASA from the end of December 2025 and supporting the transition thereafter. Geir Christian brings extensive senior leadership experience across the Norwegian biotech and life sciences sector, including multiple CFO and CEO roles in both publicly listed and privately held companies including in Algeta and Photocure. Over his career, he has led financial operations, corporate strategy, and capital market engagement for several life science organisations, giving him a deep understanding of the financial, regulatory, and operational demands of the industry.Geir Christian has also been part of Zelluna as Finance Director for over seven years, holding a key leadership role across finance and operations. He brings strong familiarity with Zelluna’s TCR-NK platform, financial strategy, and organisational priorities.
お知らせ • Nov 04+ 2 more updatesZelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million.Zelluna ASA has filed a Follow-on Equity Offering in the amount of NOK 8 million. Security Name: Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 10 Transaction Features: Rights Offering
お知らせ • Oct 10Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-In-Human Trials in the UKZelluna announced it has received positive feedback from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) following recent scientific advice. This feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for ZI-MA4-1 and supports Zelluna's planned Clinical Trial Application (CTA) submission later this year. In parallel, Zelluna has advanced preparations for the first-in-human trial of ZI-MA4- 1 by engaging with leading UK cancer centres and appointing Professoriona Thistlethwaite, Medical Oncology Consultant at The Christie in Manchester, as proposed Chief Investigator. The Christie, one of Europe's leading cancer centres and a major hub for advanced cell therapy research, will serve as a lead site for the study. Both Professor Fiona Thistlethwaite at The Christie and Dr. Andrew Furness at The Royal Marsden in London, a global leader in oncology and early-phase cell therapy studies, are expected to play central roles in the trial and have contributed to shaping its design and development strategy. Subject to CTA approval, the proposed Phase I trial will be an open-label, dose-escalation basket study evaluating the safety, tolerability and preliminary efficacy of ZI-MA4 -1 across multiple solid tumours. Prof. Fiona Thistlethwaite, medical Oncology Consultant within the Experimental Cancer Medicines Team (ECMT), Clinical Lead for the Advanced Immunotherapy and Cell Therapy (AICT) Team, The Christie, and proposed Chief Investigator for the planned trial, said "I am genuinely excited to see the progress of ZI-MA 4-1 into the clinic. I am optimistic that the dual killing mechanism of the NK cells and tumour antigen directed TCR will provide with the step-change that need in the solid tumour setting to provide the required level of tumour potential whilst avoiding tumour escape".
お知らせ • Apr 08+ 4 more updatesZelluna ASA to Report Q1, 2025 Results on May 08, 2025Zelluna ASA announced that they will report Q1, 2025 results on May 08, 2025
